FDA approves NAMENDA XR for the treatment of treatment of Alzheimer’s group dementia
Forest Laboratories, Inc. (NYSE: FRX) and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved aside the U.S. Bread and Painkiller Government on account of the treatment of middling to harsh dementia of the Alzheimer’s archetype. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA. The security and efficacy of NAMENDA XR were proper in a randomized, double-blind, placebo-controlled inquisition of 677 outpatients already bewitching a cholinesterase inhibitor. The results evidence that patients treated with NAMENDA XR shrewd statistically valuable benefits in cognition and clinical international significance compared to placebo.
NAMENDA XR longing be covered aside U.S. Unmistakeable No. 5,061,703, which is listed in the Orange Tome championing NAMENDA and expires in April 2015. In extension, Forest owns up in the air palpable applications coordinated to NAMENDA XR. The companies are determining the allot commercialization scheme and customer base timing to safeguard a moneymaking franchise.
HORSES MOUTH Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
